4,122 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by Coign Capital Advisors LLC

Coign Capital Advisors LLC purchased a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 4,122 shares of the company's stock, valued at approximately $596,000.

Several other large investors also recently made changes to their positions in the stock. MRP Capital Investments LLC increased its stake in Johnson & Johnson by 4.1% during the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after purchasing an additional 65 shares in the last quarter. Syverson Strege & Co increased its position in shares of Johnson & Johnson by 4.9% in the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after acquiring an additional 65 shares during the period. Werba Rubin Papier Wealth Management raised its stake in Johnson & Johnson by 3.3% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after acquiring an additional 66 shares during the last quarter. Denali Advisors LLC lifted its position in Johnson & Johnson by 1.3% during the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after acquiring an additional 67 shares during the period. Finally, Sage Mountain Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after purchasing an additional 67 shares during the period. Institutional investors own 69.55% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on JNJ shares. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Bank of America dropped their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $163.00 to $164.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 9th. Stifel Nicolaus cut their price target on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Finally, Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Eight equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $171.50.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $0.92 during midday trading on Tuesday, reaching $153.44. The company had a trading volume of 5,229,595 shares, compared to its average volume of 7,954,012. The firm's fifty day simple moving average is $159.38 and its 200-day simple moving average is $155.11. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a market capitalization of $369.77 billion, a P/E ratio of 23.07, a P/E/G ratio of 2.56 and a beta of 0.49. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.39%. Johnson & Johnson's dividend payout ratio is 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.